Building A Bulletproof Portfolio Around NIO Limited (NIO), Lipocine Inc. (LPCN)

NIO Limited (NYSE:NIO) has its shares plummet by -65.23% or $6.94 from its all-time high of $10.64, with NIO attaining that price back on February 26, 2019. The drop in the price of the shares saw it stand at $3.7 per share. NIO has been trading at a low of $1.19 over the past one year but it surged by 210.92% or $2.51 to reach the $3.7 mark. Following the massive rise in stock price, NIO received more attention from investors and analysts. On Monday, the stock plunged by 5.41%, which caused investors and analysts to excite about it. Following the plunge in price, the NIO beta stands at 0, implying that its volatility level has gone down by 1 back of the general market. A look at the stock’s 200-day moving average shows that it is 20.84% above while its 50-day moving average shows that it is currently 52.72% above. Compared to 11.02% average daily volatility of past month, the stock’s average volatility for this week has decreased by -1.76 as the volatility level currently stands at 9.26%.

Over the past seven days, the stock has witnessed a price surge by 0.54%. This massive rise in stock price has caught the attention of both investors and market traders. The stock has performed poorly over the past 52 weeks, dropping by -43.85% during that time frame and is now down by -7.96% since this point this year. NIO has surged by 63.72% over the past 30 days, with its equity price gaining% of its value over the past ninety days. These figures add up to see the stock record a growth of 9.14% over the past six months.

Market analysts from research firms still remain bullish about the short-term performance of NIO. Most of them are of the view that the stock would be able to reach $3.67 over the next 12 months. If that happens, then the stock would witness a -0.81% fall in its price and that would see the stock’s market cap hit an astonishing $4 Billion. Analysts view this stock as a bearish at the moment as its average rating is 3.1. According to Reuters, many of the 6 analysts covering the stock at the moment believe it is a Buy. 5 of them rated NIO as a Hold while 1 of them either rated it as a Buy or a Strong Buy. However, 0 of them advised investors to sell the stock if they have it or shouldn’t buy it if they don’t possess any.

The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a neutral position as it was able to attain 65.68 points. The trading volume now standing at 59249199 shares. The increase of 7839199 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of NIO was 51410000 shares, which is more than 1.15 times higher than its usual trading volume.

The stock is currently neutral as its Stochastic Oscillator (%D) is at 67.65%, which implies that a stability in price will be experienced for a while. Its shares P/S ratio is above the 0.45 industry average and above the 0.67 by the wider market, as LPCN’s P/S ratio currently stands at 56.04. The stock’s estimated price-earnings (P/E) multiple is 0 which is also below the 12-month price-earnings (P/E) which stands at 0. Lipocine Inc. has experienced a rise in its earnings, recording an increase rate of 17.6% in each quarter over the past five years.

The stock has an average rating of 2.5 which means that it has been rated as a Hold by most analysts. The stock is being covered by 2 analysts who gave a consensus recommendation of 2.5 which implies that it is currently in a neutral situation. Reuters looked into analysts covering Lipocine Inc., and 1 of them believe that the stock is a Hold at the moment. 1 of the analysts rated it as a Buy or a Strong Buy while the remaining analysts (0) rated it as a sell at the moment.